Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly—A Subgroup Analysis of Routine Clinical Practice Data

Table 3

Dosages of strong opioids received immediately prior to treatment with tapentadol PR.

	Aged >65 years	Aged ≤65 years
Fentanyl (transdermal)	129	36
≤25 μg/h	53	17
50 μg/h	36	7
≥75 μg/h	40	12
Oxycodone/naloxone	74^a	30
≤40 mg/day	66	23
41–80 mg/day	7	6
>80 mg/day	0	1
Oxycodone	61^a	26
≤40 mg/day	49	18
41–80 mg/day	8	7
>80 mg/day	3	1
Buprenorphine	56^a	9
≤20 μg/h	33	9
35 μg/h	12	0
52.5 μg/h	6	0
70 μg/h	4	0
Morphine	37	19^a
≤60 mg/day	26	10
61–120 mg/day	8	7
>120 mg/day	3	1
Hydromorphone	33	9^a
≤8 mg/day	8	4
9–16 mg/day	17	2
>16 mg/day	8	2

Data are number of patients. ^aData missing for one patient. PR, prolonged release.